Anthem Biosciences’ IPO puts the spotlight on India’s contract drug manufacturing sector, as investor appetite swells and global firms diversify away from China.
Anthem Biosciences’ IPO puts the spotlight on India’s contract drug manufacturing sector, as investor appetite swells and global firms diversify away from China.